Reply to Letter to Editor from Juan-Enrique Schwarze and Colleagues - Critical Appraisal on "Determining the Cost-effectiveness of Follitropin Alfa Biosimilar Compared to Follitropin Alfa Originator in Women Undergoing Fertility Treatment in France"

Overview

Journal Eur J Obstet Gynecol Reprod Biol X

Specialty Gynecology & Obstetrics

Date 2024 Sep 2

PMID 39220093

Authors

Matthieu Lehmann

Jean-Luc Pouly

Paul Barriere

Lauren Amy Boland

Samuel George Bean

Julian Jenkins

Affiliations

Soon will be listed here.

References

Steinke D, Zarroug O, Mathur R, Kendrew H, Jenkins J . Qualitative risk assessment of follicle stimulating hormone injectable products. Expert Opin Drug Deliv. 2020; 17(11):1647-1654. DOI: 10.1080/17425247.2020.1813106. View

Caro J, Briggs A, Siebert U, M Kuntz K . Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1. Value Health. 2012; 15(6):796-803. DOI: 10.1016/j.jval.2012.06.012. View

Gizzo S, Ferrando M, Lispi M, Ripellino C, Cataldo N, Buhler K . A cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy and Spain. J Med Econ. 2018; 21(11):1096-1101. DOI: 10.1080/13696998.2018.1511567. View

Barriere P, Arbo E, Jenkins J . Reply to the letter to the editor in response to 'A real-world study of ART in France (REOLA) comparing a biosimilar rFSH against the originator according to rFSH starting dose' by S. Montenegro, C. Helwig, J.-E. Schwarze, C. Castello-Bridoux, S..... J Gynecol Obstet Hum Reprod. 2023; 52(8):102644. DOI: 10.1016/j.jogoh.2023.102644. View

Grynberg M, Cedrin-Durnerin I, Raguideau F, Herquelot E, Luciani L, Porte F . Comparative effectiveness of gonadotropins used for ovarian stimulation during assisted reproductive technologies (ART) in France: A real-world observational study from the French nationwide claims database (SNDS). Best Pract Res Clin Obstet Gynaecol. 2023; 88:102308. DOI: 10.1016/j.bpobgyn.2022.102308. View

Grynberg M, Murphy C, Dore C, Fresneau L, Paillet S, Petrica N . A cost-effectiveness analysis comparing the originator follitropin alfa to its biosimilars in patients undergoing a medically assisted reproduction program from a French perspective. J Med Econ. 2018; :1-15. DOI: 10.1080/13696998.2018.1551226. View

Somigliana E, Bertoli M, Caputo A, Reschini M, Bardiani I, Bruno G . Wastage of gonadotropins during IVF cycles: Real life data from two Italian infertility centers. Eur J Obstet Gynecol Reprod Biol. 2021; 267:56-60. DOI: 10.1016/j.ejogrb.2021.10.013. View

Martin J, Mahutte N, Arici A, Sakkas D . Impact of duration and dose of gonadotrophins on IVF outcomes. Reprod Biomed Online. 2006; 13(5):645-50. DOI: 10.1016/s1472-6483(10)60654-2. View

Baker V, Brown M, Luke B, Smith G, Ireland J . Gonadotropin dose is negatively correlated with live birth rate: analysis of more than 650,000 assisted reproductive technology cycles. Fertil Steril. 2015; 104(5):1145-52.e1-5. PMC: 4896751. DOI: 10.1016/j.fertnstert.2015.07.1151. View

10.

Foxon G, Mitchell P, Turner N, McConnell A, Kendrew H, Jenkins J . Bemfola fixed dose pens potentially reduce drug wastage and associated costs of infertility treatment. Hum Fertil (Camb). 2017; 21(4):275-280. DOI: 10.1080/14647273.2017.1328131. View

11.

Hershkop E, Segal L, Fainaru O, Kol S . 'Model' versus 'everyday' patients: can randomized controlled trial data really be applied to the clinic?. Reprod Biomed Online. 2016; 34(3):274-279. DOI: 10.1016/j.rbmo.2016.11.010. View

12.

Barriere P, Hamamah S, Arbo E, Avril C, Salle B, Pouly J . A real-world study of ART in France (REOLA) comparing a biosimilar rFSH against the originator according to rFSH starting dose. J Gynecol Obstet Hum Reprod. 2022; 52(1):102510. DOI: 10.1016/j.jogoh.2022.102510. View

13.

Xue W, Lloyd A, Falla E, Roeder C, Papsch R, Buhler K . A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany. Int J Womens Health. 2019; 11:319-331. PMC: 6524790. DOI: 10.2147/IJWH.S193048. View

14.

Barriere P, Porcu-Buisson G, Hamamah S . Cost-Effectiveness Analysis of the Gonadotropin Treatments HP-hMG and rFSH for Assisted Reproductive Technology in France: A Markov Model Analysis. Appl Health Econ Health Policy. 2017; 16(1):65-77. DOI: 10.1007/s40258-017-0361-7. View